Skip to main content
Epistemic News
Latest⚡ Catch UpBlindspotSources
Epistemic News

Every claim sourced. Every perspective labeled. News verified by AI, never edited by humans.

AboutMethodologyStatusPricingPrivacyTerms

© 2026 Epistemic News · Built by Sardonyx Software

← Back to sources

Ars Technica

Left-CenterindependentUS
Factual Reporting
High Factual Reporting
MBFC Rating
View on Media Bias / Fact Check →

Accuracy over time(last 7 days)

9
stories cited in
46%
avg confidence score
71%
claims verified
29%
claims disputed

Recent stories citing Ars Technica(last 9 in 7 days)

51%FDA Advisory Committee Votes 9-0 to Support Moderna mRNA-1010 Flu Vaccine1d ago41%NAACP Lawsuit Against xAI Over Mississippi Gas Turbines Faces Potential Federal Intervention3d ago63%DOJ Intervenes in xAI Memphis Data Center Lawsuit; RT Reports Grok Integration in Palantir Military Systems3d ago43%OpenAI Leaked Financials Report $13 Billion Revenue Against $21 Billion Losses With IPO Filing Planned3d ago37%Reported SpaceX Acquisition of Cursor AI Tool Remains Unverified Amid Conflicting Claims3d ago51%Google Releases Android 17 and Wear OS 7 for Pixel Devices3d ago50%VA Study Analyzes 2024-2025 COVID-19 Vaccine and Major Adverse Cardiovascular Events in Over One Million Patients4d ago46%UK Announces Social Media Restrictions for Under-16s Targeting Major Platforms4d ago35%Nvidia Seeks Over $25 Billion in Bonds for First Time Since 20214d ago

Claim track record

Consensus facts10 (71%)
Disputed claims4 (29%)

Across 9 stories in the last 7 days. Consensus facts are claims corroborated across multiple sources; disputed claims reflect source disagreements.

All recent coverage(1 in last 72h)

FDA Advisory Committee Votes 9-0 to Support Moderna mRNA-1010 Flu Vaccine

51
2 sources2 min readScience4 blindspots
LeftCenterRight
Bias ratings by MBFC
✅ 12 verified🤝 100% model agreement
Framing Analysis1 balanced · 0 biased · 0 diverge from source label
WSJ
Ars Technicaagency drama, Trump official refused

FDA advisors voted unanimously on Friday to recommend approval of Moderna’s mRNA-1010 seasonal flu vaccine, branded mFlusiva. Large Phase 3 trials showed 27 percent greater effectiveness than standard shots in adults over 50 and stronger immune responses than high-dose vaccines in those over 65, with a generally favorable safety profile. Earlier attempts by Trump appointees to block review were noted in reporting.

WSJArs Technica🏢
Synthesized by AI from 2 sources
View all 2 sources
[WSJ] FDA Votes in Favor of Benefit-Risk Profile for Moderna’s Flu Vaccine[Ars Technica 🏢] FDA advisors unanimously vote to approve Moderna's mRNA after agency drama